Our Heritage is In Hematology

American Society of Hematology Annual Meeting 2020

For more than 10 years, we have pioneered the science behind IDH mutations in hematologic malignancies and PKR activation in rare hemolytic anemias.

IDH-US-0215 11/20

Driven by the desire to push boundaries, we combined our knowledge of the metabolome and the genome to develop precision medicines for patients with cancers that harbor IDH mutations starting with acute myeloid leukemia.

X Close

Leveraging our prolific scientific platform, we are building a pipeline of disease-modifying medicines designed to significantly slow, halt or reverse rare genetic metabolic diseases.

X Close